STAT+: BIO joins the legal fight against Medicare pilot that ties drug prices to peer countries
The model is a test of Trump's most-favored nation approach to drug pricing, though its impact is likely to be limited.
The Biotechnology Innovation Organization (BIO) and two California-based biotech trade groups filed a complaint in the U.S. District Court for the Northern District of California on Friday. The lawsuit challenges the Global Benchmark for Efficient Drug Pricing demonstration, referred to as GLOBE, a pilot program from the Trump administration intended to align Medicare drug prices with those in peer countries.
The complaint asserts that the GLOBE model oversteps the statutory authority of Medicare and seeks to halt the program. The Centers for Medicare and Medicaid Services did not immediately respond to a request for comment regarding the filing.
Brief written by urgent.news from STAT News, Fierce Healthcare, Healthcare Dive — 3 reports on this story. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
